Skip to main content
Top
Published in: BMC Infectious Diseases 1/2020

01-12-2020 | Vancomycin | Research article

The effect of body mass index and creatinine clearance on serum trough concentration of vancomycin in adult patients

Authors: Yuyan Pan, Xiaomei He, Xinyu Yao, Xiaofeng Yang, Fengjiao Wang, Xinyuan Ding, Wenjuan Wang

Published in: BMC Infectious Diseases | Issue 1/2020

Login to get access

Abstract

Background

The aim of this study was to evaluate the influence of patient body mass index (BMI) and estimated creatinine clearance (CrCl) on serum vancomycin concentrations to define a possible optimal dosage regimen in overweight patients based on data obtained during therapeutic drug monitoring.

Methods

This retrospective study used data collected from January 2017 to January 2019. Adult patients (n = 204) received vancomycin treatment at a dose of 1000 mg every 12 h and underwent serum monitoring. Data collected included patient disease category, sex, age, height, weight, vancomycin concentrations, and serum creatinine. The CrCl values were estimated using the Cockcroft-Gault formula. In this study, statistical comparisons were performed on the results of patients according to serum vancomycin concentration.

Results

Serum vancomycin concentration was significantly related to BMI (P <  0.001) and CrCl (P <  0.05) in adult patients. Furthermore, the trough serum vancomycin concentration showed a logarithmic correlation with BMI (R = − 0.5108, 95% CI: − 0.6082 to − 0.3982, P <  0.001) and CrCl (R = − 0.5739, 95% CI: − 0.6616 to − 0.4707, P <  0.001). The multivariate analysis showed that BMI and CrCl are independent contributors to the trough vancomycin concentration. Moreover, some of the patients with higher BMI (≥ 24 kg/m2) met the goal trough concentration after an adjustment from 1000 mg every 12 h to 1000 mg every 8 h.

Conclusions

Serum vancomycin concentration decreases progressively with increasing BMI and the augmentation in CrCl in adult patients. The trough concentration of vancomycin should be continuously monitored for patients with a BMI ≥ 24 kg/m2, and the dosage regimen should be adjusted to reach the target trough concentration in these patients to reduce the impact of BMI.
Literature
1.
go back to reference Butler-Laporte G, De L'Étoile-Morel S, Cheng MP, McDonald EG, Lee TC. MRSA colonization status as a predictor of clinical infection: a systematic review and meta-analysis. J Inf Secur. 2018;77(6):489–95. Butler-Laporte G, De L'Étoile-Morel S, Cheng MP, McDonald EG, Lee TC. MRSA colonization status as a predictor of clinical infection: a systematic review and meta-analysis. J Inf Secur. 2018;77(6):489–95.
2.
go back to reference Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev. 2014;77:50–7.CrossRef Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev. 2014;77:50–7.CrossRef
3.
go back to reference Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the society of infectious diseases pharmacists. Clin Infect Dis. 2009;49(3):325–7.CrossRef Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the society of infectious diseases pharmacists. Clin Infect Dis. 2009;49(3):325–7.CrossRef
4.
go back to reference Ji XW, Ji SM, He XR, Zhu X, Chen R, Lu W. Influences of renal function descriptors on population pharmacokinetic modeling of vancomycinin Chinese adult patients. Acta Pharmacol Sin. 2018;39(2):286–93.CrossRef Ji XW, Ji SM, He XR, Zhu X, Chen R, Lu W. Influences of renal function descriptors on population pharmacokinetic modeling of vancomycinin Chinese adult patients. Acta Pharmacol Sin. 2018;39(2):286–93.CrossRef
5.
go back to reference Nelson NR, Morbitzer KA, Jordan JD, Rhoney DH. The impact of capping creatinine clearance on achieving therapeutic vancomycin concentrations in neurocritically III patients with traumatic brain injury. Neurocrit Care. 2019;30(1):126–31.CrossRef Nelson NR, Morbitzer KA, Jordan JD, Rhoney DH. The impact of capping creatinine clearance on achieving therapeutic vancomycin concentrations in neurocritically III patients with traumatic brain injury. Neurocrit Care. 2019;30(1):126–31.CrossRef
6.
go back to reference Padgett D, Ostrenga A, Lepard L. Comparison of methods of estimating creatinine clearance in pediatric patients. Am J Health Syst Pharm. 2017;74(11):826–30.CrossRef Padgett D, Ostrenga A, Lepard L. Comparison of methods of estimating creatinine clearance in pediatric patients. Am J Health Syst Pharm. 2017;74(11):826–30.CrossRef
7.
go back to reference Romão CM, Pereira RC, Shimizu MHM, Furukawa LNS. N-acetyl-l-cysteine exacerbates kidney dysfunction caused by a chronic high-sodium diet in renal ischemia and reperfusion rats. Life Sci. 2019;231:116544.CrossRef Romão CM, Pereira RC, Shimizu MHM, Furukawa LNS. N-acetyl-l-cysteine exacerbates kidney dysfunction caused by a chronic high-sodium diet in renal ischemia and reperfusion rats. Life Sci. 2019;231:116544.CrossRef
8.
go back to reference Wang K, Kestenbaum B. Proximal tubular secretory clearance: a neglected partner of kidney function. Clin J Am Soc Nephrol. 2018;13(8):1291–6.CrossRef Wang K, Kestenbaum B. Proximal tubular secretory clearance: a neglected partner of kidney function. Clin J Am Soc Nephrol. 2018;13(8):1291–6.CrossRef
9.
go back to reference Gerchman F, Tong J, Utzschneider KM, Zraika S, Udayasankar J, McNeely MJ, Carr DB, Leonetti DL, Young BA, de Boer IH, Boyko EJ, Fujimoto WY, Kahn SE. Body mass index is associated with increased creatinine clearance by a mechanism independent of body fat distribution. J Clin Endocrinol Metab. 2009;94(10):3781–8.CrossRef Gerchman F, Tong J, Utzschneider KM, Zraika S, Udayasankar J, McNeely MJ, Carr DB, Leonetti DL, Young BA, de Boer IH, Boyko EJ, Fujimoto WY, Kahn SE. Body mass index is associated with increased creatinine clearance by a mechanism independent of body fat distribution. J Clin Endocrinol Metab. 2009;94(10):3781–8.CrossRef
10.
go back to reference Rutter WC, Hall RG, Burgess DS. Impact of total body weight on rate of acute kidney injury in patients treated with piperacillin-tazobactam and vancomycin. Am J Health Syst Pharm. 2019;76(16):1211–7.CrossRef Rutter WC, Hall RG, Burgess DS. Impact of total body weight on rate of acute kidney injury in patients treated with piperacillin-tazobactam and vancomycin. Am J Health Syst Pharm. 2019;76(16):1211–7.CrossRef
11.
go back to reference Pokorná P, Šíma M, Černá O, Allegaert K, Tibboel D, Slanař O. Actual body weight-based vancomycin dosing in neonates. J Chemother. 2019;31(6):307–12.CrossRef Pokorná P, Šíma M, Černá O, Allegaert K, Tibboel D, Slanař O. Actual body weight-based vancomycin dosing in neonates. J Chemother. 2019;31(6):307–12.CrossRef
12.
go back to reference Vitolo E, Santini E, Salvati A, Volterrani D, Duce V, Bruno RM, Solini A. Metabolic and hormonal determinants of glomerular filtration rate and renal hemodynamics in severely obese individuals. Obes Facts. 2016;9(5):310–20.CrossRef Vitolo E, Santini E, Salvati A, Volterrani D, Duce V, Bruno RM, Solini A. Metabolic and hormonal determinants of glomerular filtration rate and renal hemodynamics in severely obese individuals. Obes Facts. 2016;9(5):310–20.CrossRef
13.
go back to reference Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF, Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55.CrossRef Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF, Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55.CrossRef
14.
go back to reference Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52(4):1330–6.CrossRef Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52(4):1330–6.CrossRef
15.
go back to reference Crass RL, Dunn R, Hong J, Krop LC, Pai MP. Dosing vancomycin in the super obese: less is more. J Antimicrob Chemother. 2018;73(11):3081–6.CrossRef Crass RL, Dunn R, Hong J, Krop LC, Pai MP. Dosing vancomycin in the super obese: less is more. J Antimicrob Chemother. 2018;73(11):3081–6.CrossRef
16.
go back to reference Adane ED, Herald M, Koura F. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy. 2015;35(2):127–39.CrossRef Adane ED, Herald M, Koura F. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy. 2015;35(2):127–39.CrossRef
17.
go back to reference Disease control Ministry of Health of the People's Republic of China. The guidelines of Chinese adult overweight and obesity prevention and control. Beijing: People’s Medical Publishing House; 2006. p. 1–3. Disease control Ministry of Health of the People's Republic of China. The guidelines of Chinese adult overweight and obesity prevention and control. Beijing: People’s Medical Publishing House; 2006. p. 1–3.
18.
go back to reference Eknoyan G, Levin N. NKF-K/DOQI clinical practice guidelines: update 2000. Foreword Am J Kidney Dis. 2001;37(1 Suppl 1):S5–6.CrossRef Eknoyan G, Levin N. NKF-K/DOQI clinical practice guidelines: update 2000. Foreword Am J Kidney Dis. 2001;37(1 Suppl 1):S5–6.CrossRef
19.
go back to reference Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.CrossRef Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.CrossRef
20.
go back to reference Estes KS, Derendorf H. Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res. 2010;15(12):533–43.CrossRef Estes KS, Derendorf H. Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res. 2010;15(12):533–43.CrossRef
21.
go back to reference Heble DE Jr, McPherson C, Nelson MP, Hunstad DA. Vancomycin trough concentrations in overweight or obese pediatric patients. Pharmacotherapy. 2013;33(12):1273–7.CrossRef Heble DE Jr, McPherson C, Nelson MP, Hunstad DA. Vancomycin trough concentrations in overweight or obese pediatric patients. Pharmacotherapy. 2013;33(12):1273–7.CrossRef
23.
go back to reference Hayes A, Gearon E, Backholer K, Bauman A, Peeters A. Age-specific changes in BMI and BMI distribution among Australian adults using cross-sectional surveys from 1980 to 2008. Int J Obes. 2015;39(8):1209–16.CrossRef Hayes A, Gearon E, Backholer K, Bauman A, Peeters A. Age-specific changes in BMI and BMI distribution among Australian adults using cross-sectional surveys from 1980 to 2008. Int J Obes. 2015;39(8):1209–16.CrossRef
24.
go back to reference Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87.CrossRef Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87.CrossRef
25.
go back to reference Bi J, Li X, Liu J, Chen D, Li S, Hou J, Zhou Y, Zhu S, Zhao Z, Qin E, Wei Z. Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B. Sci Rep. 2017;7(1):7893.CrossRef Bi J, Li X, Liu J, Chen D, Li S, Hou J, Zhou Y, Zhu S, Zhao Z, Qin E, Wei Z. Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B. Sci Rep. 2017;7(1):7893.CrossRef
26.
go back to reference Tanigawara Y, Sato R, Morita K, Kaku M, Aikawa N, Shimizu K. Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(11):3754–62.CrossRef Tanigawara Y, Sato R, Morita K, Kaku M, Aikawa N, Shimizu K. Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(11):3754–62.CrossRef
Metadata
Title
The effect of body mass index and creatinine clearance on serum trough concentration of vancomycin in adult patients
Authors
Yuyan Pan
Xiaomei He
Xinyu Yao
Xiaofeng Yang
Fengjiao Wang
Xinyuan Ding
Wenjuan Wang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2020
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-020-05067-7

Other articles of this Issue 1/2020

BMC Infectious Diseases 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.